Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia

NCT02298933 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

NIH

Sponsor class

Conditions

Thrombocytopenia
Alloimmune Platelet Refractoriness

Interventions

DRUG: Eculizumab

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)